Daily Sepsis Research Analysis
Three impactful sepsis-related studies emerged today: a randomized trial found transcranial Doppler–guided norepinephrine titration reduced cerebral hypoperfusion and improved neurologic status in sepsis-induced encephalopathy without changing ICU mortality; a nationwide U.S. cohort quantified markedly elevated severe maternal morbidity and sepsis risk in pregnancies complicated by chronic kidney disease; and mechanistic work implicated cold-stimulated epithelial exosomal HMGB1 driving sepsis-in
Summary
Three impactful sepsis-related studies emerged today: a randomized trial found transcranial Doppler–guided norepinephrine titration reduced cerebral hypoperfusion and improved neurologic status in sepsis-induced encephalopathy without changing ICU mortality; a nationwide U.S. cohort quantified markedly elevated severe maternal morbidity and sepsis risk in pregnancies complicated by chronic kidney disease; and mechanistic work implicated cold-stimulated epithelial exosomal HMGB1 driving sepsis-induced acute lung injury via RAGE/Nrf2/HO-1.
Research Themes
- Individualized hemodynamic targets in sepsis-induced encephalopathy using transcranial Doppler
- Maternal sepsis and severe morbidity risk in pregnancies with chronic kidney disease
- Exosomal HMGB1/RAGE signaling driving sepsis-induced acute lung injury
Selected Articles
1. Norepinephrine titration in patients with sepsis-induced encephalopathy: cerebral pulsatility index compared to mean arterial pressure guided protocol: randomized controlled trial.
In a single-center RCT of 112 sepsis-induced encephalopathy patients, norepinephrine titration guided by transcranial Doppler pulsatility index achieved fewer cerebral hypoperfusion episodes and higher discharge GCS without reducing ICU mortality. Hemodynamics, lactate, SOFA, norepinephrine dose, and ICU length of stay were otherwise similar versus standard MAP ≥65 mmHg targeting.
Impact: This trial operationalizes individualized cerebrovascular-targeted hemodynamic management in sepsis, demonstrating measurable neurophysiologic benefits despite neutral mortality. It offers a practical monitoring target (PI<1.3) that could inform future neuroprotective strategies in sepsis.
Clinical Implications: For patients with sepsis-induced encephalopathy, incorporating TCD-derived pulsatility index targets may reduce cerebral hypoperfusion and improve neurologic status when available, while maintaining standard MAP goals. Implementation should be in centers with TCD expertise and integrated into multimodal neuro-monitoring.
Key Findings
- No significant difference in ICU mortality between TCD-PI–guided vs MAP≥65 mmHg strategies (p=0.174).
- Fewer episodes of cerebral hypoperfusion (CPP <60 mmHg) in the TCD group (p=0.018).
- Higher Glasgow Coma Scale at ICU discharge in the TCD group (median 15; p=0.014).
- Higher MAP at end of norepinephrine infusion in the TCD group (mean 69.54±10.42; p=0.002).
- No differences in heart rate abnormalities, total norepinephrine dose, lactate, SOFA, or ICU length of stay.
Methodological Strengths
- Prospective randomized controlled design with prespecified registration (NCT05842616).
- Objective neuro-hemodynamic monitoring using transcranial Doppler PI alongside standard MAP targets.
Limitations
- Single-center design and modest sample size may be underpowered for mortality differences.
- Open-label physiologic intervention without blinding; external validity depends on TCD availability and expertise.
Future Directions: Multicenter trials should test TCD-PI–guided targets on validated neurologic endpoints (delirium, long-term cognition) and integrate continuous cerebrovascular autoregulation metrics. Comparative effectiveness versus other neuromonitoring modalities is warranted.
BACKGROUND: Although surviving sepsis campaign (SSC) guidelines are the standard for sepsis and septic shock management, outcomes are still unfavourable. Given that perfusion pressure in sepsis is heterogeneous among patients and within the same patient; we evaluated the impact of individualized hemodynamic management via the transcranial Doppler (TCD) pulsatility index (PI) on mortality and outcomes among sepsis-induced encephalopathy (SIE) patients.
METHODS: In this prospective, single-center randomized controlled study, 112 patients with SIE were randomly assigned. Mean arterial pressure (MAP) and norepinephrine (NE) titration were guided via the TCD pulsatility index to achieve a pulsatility index < 1.3 in Group I, whereas the SSC guidelines were used in Group II to achieve a MAP ≥ 65 mmHg. The primary outcome was intensive care unit (ICU) mortality and the secondary outcomes were; MAP that was measured invasively and values were recorded; daily in the morning, at the end of NE infusion and the end of ICU stay, duration of ICU stay, cerebral perfusion pressure (CPP), sequential organ failure assessment (SOFA) score, norepinephrine titration and Glasgow coma scale (GCS) score at discharge.
RESULTS: ICU mortality percentage wasnt significantly different between the two groups (p value 0.174). There was a significant increase in the MAP at the end of norepinephrine infusion (mean value of 69.54 ± 10.42 and p value 0.002) and in the GCS score at ICU discharge (Median value of 15 and p value 0.014) in the TCD group, and episodes of cerebral hypoperfusion with CPP < 60 mmHg, were significantly lower in the TCD group (median value of 2 and p value 0.018). Heart rate values, number of episodes of tachycardia or bradycardia, Total norepinephrine dosing, duration of norepinephrine infusion, SOFA score, serum lactate levels, and ICU stay duration werent significantly different between the two groups.
CONCLUSIONS: Individualizing hemodynamic management via the TCD pulsatility index in SIE patients was not associated with significant mortality reduction. However, it reduces episodes of cerebral hypoperfusion and improves GCS outcome but doesn't significantly affect heart rate values, SOFA score, serum lactate level, length of ICU stay, total NE dosing, and duration of NE infusion.
TRIAL REGISTRATION: The clinical trial was registered on clinucaltrials.gov under the identifier NCT05842616 https://clinicaltrials.gov/study/NCT05842616?cond=NCT05842616&rank=1 on 6-May-2023 before the enrolment of the first patient.
2. Cold stimulated bronchial epithelial cells derived exosomes HMGB1 aggravates bronchial epithelial cells injury.
Cold-stimulated bronchial epithelial cell–derived exosomes were enriched in HMGB1 and exacerbated sepsis-induced acute lung injury by engaging RAGE and suppressing Nrf2/HO-1 antioxidant signaling. Genetic disruption of RAGE or HMGB1 abrogated these injurious effects, establishing a causal HMGB1–RAGE axis.
Impact: Identifies a discrete exosome-mediated HMGB1–RAGE signaling pathway linking environmental cold stress to worsened SALI, offering a modifiable mechanistic target. This bridges epithelial cell biology, extracellular vesicles, and sepsis lung injury.
Clinical Implications: While preclinical, the HMGB1–RAGE axis suggests potential therapeutic avenues (e.g., HMGB1 neutralization, RAGE antagonism) and environmental/thermal management considerations to mitigate lung injury risk during sepsis.
Key Findings
- Cold-stimulated epithelial exosomes (mean size ~123.6 nm) were enriched for HMGB1 by proteomics.
- Administration of CS-BECs-exo increased oxidative stress and inflammatory responses in SALI models.
- CS-BECs-exo upregulated RAGE and downregulated Nrf2 and HO-1 in lung tissue.
- Genetic knockout or silencing of RAGE abrogated the injurious effects of CS-BECs-exo.
- HMGB1 knockout or silencing similarly abolished CS-BECs-exo–induced injury, confirming HMGB1–RAGE dependence.
Methodological Strengths
- Comprehensive exosome characterization (TEM, NTA) and unbiased proteomics.
- Causal validation using RAGE and HMGB1 knockout and siRNA models.
Limitations
- Preclinical models with limited translational data; exact clinical exposure parameters for cold stimulation are not defined.
- Quantitative dosing, time-course, and sample size details are not fully specified in the abstract.
Future Directions: Translate findings to clinically relevant models, test pharmacologic HMGB1/RAGE blockade, and delineate thermal exposure thresholds that modulate exosomal signaling in human airways.
The aim of this study was to reveal the mechanism of cold stimulation (CS)-bronchial epithelial cells (BECs) derived exosomes (CS-BECs-exo) aggravated sepsis induced acute lung injury (SALI). CS-BECs-exo were separated by differential centrifugation and were characterized. Proteomics, immunoprecipitation, and RAGE knockout (RAGE) mice were used to investigate the mechanism of CS-BECs-exo aggravated SALI. The results of transmission electron microscope (TEM) showed that CS-BECs-exo showed a double-layer membrane structure like a saucer. Nanoparticle tracking analysis (NTA) particle size analysis showed that the average particle size of CS-BECs-exo was 123.6 nm. The results of proteomics showed that the expression level HMGB1 was significantly increased in CS-BECs-exo compared with BECs-exo. CS-BECs-exo significantly increased oxidative stress and inflammatory reaction of SALI. In addition, CS-BECs-exo significantly increased RAGE and decreased the levels of Nrf-2 and OH-1. RAGE knockout (RAGE KO) and silence of RAGE (RAGE siRNA) significantly canceled the effects of CS-BECs-exo on SALI. HMGB1 knockout (HMGB1) and silence of HMGB1 also significantly (HMGB1 siRNA) canceled the effects of CS-BECs-exo on SALI. In conclusion, CS-BECs-exo aggravated ALI in sepsis via HMGB1/RAGE/Nrf-2/OH-1 signal pathway.
3. Risk of severe maternal morbidity and mortality among pregnant patients with chronic kidney disease.
In a population-based U.S. cohort of 38.37 million deliveries, chronic kidney disease was associated with a six-fold higher risk of severe maternal morbidity and a four-fold higher risk of maternal death. Sepsis risk was particularly elevated (aRR 9.0), with consistent risk across CKD subtypes and stages, underscoring the need for intensified surveillance and infection prevention in CKD pregnancies.
Impact: Provides definitive, contemporary risk quantification for severe maternal morbidity—including sepsis—in CKD pregnancies at national scale, informing risk stratification and policy.
Clinical Implications: Pregnant patients with CKD warrant multidisciplinary, high-acuity care with sepsis prevention bundles, early infection screening, and close peripartum monitoring. Resource allocation and counseling should reflect elevated SMM and mortality risks, particularly for advanced CKD and high-risk subtypes.
Key Findings
- Among 38,374,326 deliveries, 95,272 (0.2%) had CKD.
- CKD associated with higher severe maternal morbidity (12.2% vs 0.7%; aRR 6.4, 95% CI 6.0–6.8).
- Sepsis risk markedly elevated in CKD (aRR 9.0, 95% CI 7.6–10.5); acute renal failure aRR 21.7.
- Maternal death increased with CKD (aRR 4.1, 95% CI 2.9–5.8).
- Risk elevation consistent across CKD subtypes/stages and renal transplant history; notable racial aPAF (Black individuals aPAF 4.0%).
Methodological Strengths
- Nationwide, population-based cohort with extremely large sample size and adjusted relative risks.
- Granular analysis across CKD stages, subtypes, transplant status, and population attributable fractions.
Limitations
- Administrative coding may introduce misclassification; residual confounding cannot be excluded.
- Retrospective hospitalization data limit causal inference and capture primarily in-hospital outcomes.
Future Directions: Prospective registries should validate sepsis phenotypes, evaluate preventive strategies, and refine risk prediction models incorporating CKD stage and social determinants.
BACKGROUND: Chronic kidney disease is a significant cause of adverse obstetric outcomes. However, there are few studies assessing the risk of severe maternal morbidity and mortality among patients with chronic kidney disease and no studies assessing the association between individual indicators of severe maternal morbidity and chronic kidney disease. OBJECTIVE: To evaluate the risk of severe maternal morbidity and mortality among pregnant patients with chronic kidney disease. STUDY DESIGN: This was a population-based, retrospective cohort study including U.S. delivery hospitalizations from 2010-2020 utilizing the Healthcare Cost & Utilization Project National Inpatient Sample database. Patients were identified as having a delivery hospitalization, chronic kidney disease, and severe maternal morbidity using International Classification Diagnoses codes (9 RESULTS: Among the 38,374,326 parturients in this study, 95,272 (0.2%) had chronic kidney disease. The risk of severe maternal morbidity was higher for those with chronic kidney disease (12.2% vs 0.7%, aRR 6.4, 95% CI 6.0-6.8) compared to those without. Among severe maternal morbidity indicators, those with chronic kidney disease were at highest risk for acute renal failure (aRR 21.7, 95% CI 19.8-23.7) and sepsis (aRR 9.0, 95% CI 7.6-10.5). Chronic kidney disease was also associated with an increased risk of maternal death (aRR 4.1, 95% CI 2.9-5.8). Black individuals had higher adjusted population attributable fraction (aPAF) between severe maternal morbidity and chronic kidney disease (aPAF 4.0%, 95% CI 3.6-4.3). Increased risk of severe maternal morbidity was associated with all chronic kidney disease subtypes, stages, and a history of renal transplant. Maternal death was significantly associated with diabetic nephropathy, renovascular, and obstructive or unspecified renal disease (aRR 7.3-14.1), as well as stages 3-5 of chronic kidney disease and a history of renal transplant (aRR 15.5-32.6). Risk of severe maternal morbidity and mortality were similar in those with a history of renal transplant and those with stage 1 chronic kidney disease. The number needed to treat with renal transplant to prevent 1 severe maternal morbidity event or maternal death in those with stages 3-5 chronic kidney disease was 2.6 (95% CI 2.4-2.9) and 45.0 (95% CI 31.0-82.0), respectively. CONCLUSION: Chronic kidney disease in pregnancy was significantly associated with severe maternal morbidity, mortality, and other adverse perinatal outcomes, warranting close surveillance and multidisciplinary management throughout pregnancy.